Lactoferrin-Anchored Tannylated Mesoporous Silica Nanomaterials for Enhanced Osteo-Differentiation Ability
Sung Hyun Noh,
Han-Saem Jo,
Somang Choi,
Hee Gyeong Song,
Hak-Jun Kim,
Keung Nyun Kim,
Sung Eun Kim,
Kyeongsoon Park
Affiliations
Sung Hyun Noh
Department of Neurosurgery, National Health Insurance Service Ilsan Hospital, #100, Ilsan-ro, Ilsan-donggu, Gyeonggi-do, Goyang-si 10444, Korea
Han-Saem Jo
Department of Systems Biotechnology, Chung-Ang University, Gyeonggi-do, Anseong-si 17546, Korea
Somang Choi
Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #148, Gurodong-ro, Guro-gu, Seoul 08308, Korea
Hee Gyeong Song
Department of Systems Biotechnology, Chung-Ang University, Gyeonggi-do, Anseong-si 17546, Korea
Hak-Jun Kim
Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #148, Gurodong-ro, Guro-gu, Seoul 08308, Korea
Keung Nyun Kim
Department of Neurosurgery, Spine and Spinal Cord Institute, Severance Hospital, Yonsei University College of Medicine, #50, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Sung Eun Kim
Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #148, Gurodong-ro, Guro-gu, Seoul 08308, Korea
Kyeongsoon Park
Department of Systems Biotechnology, Chung-Ang University, Gyeonggi-do, Anseong-si 17546, Korea
In the present study, we created lactoferrin-anchored mesoporous silica nanomaterials with absorbed tannic acid (LF/TA-MSNs) and evaluated the effect of these LF/TA-MSNs on the in vitro osteo-differentiation ability of adipose-derived stem cells (ADSCs) by testing alkaline phosphatase (ALP) level, calcium accumulation, and expression of osteo-differentiation-specific genes, including osteocalcin (OCN) and osteopontin (OPN). Both bare MSNs and LF/TA-MSNs exhibited round nano-particle structures. The LF/TA-MSNs demonstrated prolonged LF release for up to 28 days. Treatment of ADSCs with LF (50 μg)/TA-MSNs resulted in markedly higher ALP level and calcium accumulation compared to treatment with LF (10 μg)/TA-MSNs or bare MSNs. Furthermore, LF (50 μg)/TA-MSNs remarkably increased mRNA levels of osteo-differentiation-specific genes, including OCN and OPN, compared to MSNs or LF (10 μg)/TA-MSNs. Together, these data suggest that the ability of LF/TA-MSNs to enhance osteo-differentiation of ADSCs make them a possible nanovehicle for bone healing and bone regeneration in patients with bone defect or disease.
